Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Celator(R) Pharmaceuticals Receives Notice of Allowance on U.S. Patent for CombiPlex(R) Technology Platform

Abstract:
Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex® technology platform (U.S. patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukemia and colorectal cancer.

Celator(R) Pharmaceuticals Receives Notice of Allowance on U.S. Patent for CombiPlex(R) Technology Platform

Princeton, NJ | Posted on April 12th, 2010

CombiPlex is a unique approach in the development of combination drug therapies used for treating cancer. It is the only approach using drug carriers to deliver synergistic ratios of cancer drug combinations. In contrast to conventional combination chemotherapies, Celator recognized that different ratios of the same two (or more) drugs can be synergistic, additive and even antagonistic. CombiPlex identifies a synergistic ratio of the drugs and locks this ratio in nano-scale (about 100 times smaller than a red blood cell) carriers that are able to deliver and maintain the synergistic drug ratio after injection in patients. This extended delivery of a synergistic ratio of drugs is intended to increase the effectiveness of the combination and improve clinical outcomes.

"This broad allowance protects our ability to utilize the CombiPlex platform with a wide variety of antineoplastic agents, opening up numerous potential combinations for investigation and possible commercialization," said Dr. Lawrence Mayer, president and head or research at Celator Pharmaceuticals.

Celator received similar patent protection for CombiPlex from the European Patent Office in 2006. The U.S. patent will extend until at least 2024.

"Extending patent protection of CombiPlex to the US strengthens our intellectual property portfolio as we advance our pipeline of cancer therapies and collaborative programs with other pharmaceutical companies," said Scott Jackson, CEO of Celator Pharmaceuticals. "The technology has already yielded promising clinical data. In December, we reported encouraging interim data from the first of two randomized Phase 2 clinical studies in patients with Acute Myeloid Leukemia treated with our lead drug, CPX-351, and we will report additional efficacy and safety data with CPX-351 later this year."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

For more information, please click here

Copyright © PRWeb

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Two UCSB Professors Receive Early Career Research Awards: The Department of Energy’s award for young scientists acknowledges UC Santa Barbara’s standing as a top tier research institution May 29th, 2015

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Nanomedicine

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Announcements

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Two UCSB Professors Receive Early Career Research Awards: The Department of Energy’s award for young scientists acknowledges UC Santa Barbara’s standing as a top tier research institution May 29th, 2015

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Patents/IP/Tech Transfer/Licensing

SouthWest NanoTechnologies Introduces AgeNT™ Transparent Conductor System at SID Display Week, Booth #543 May 28th, 2015

Researchers develop new way to manufacture nanofibers May 21st, 2015

Novel superconducting undulator provides first x-ray light at ANKA May 1st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Nanobiotechnology

New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project